Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management-Reference-Cited by-同舟云学术

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management

Published:2015-08-17 Issue:32 Volume:6 Page:33982-33992
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Del Prete Michela¹,Giampieri Riccardo¹,Loupakis Fotios²,Prochilo Tiziana³,Salvatore Lisa²,Faloppi Luca¹,Bianconi Maristella¹,Bittoni Alessandro¹,Aprile Giuseppe⁴,Zaniboni Alberto³,Falcone Alfredo²,Scartozzi Mario⁵,Cascinu Stefano¹

Affiliation:

1. Medical Oncology, AO Ospedali Riuniti-Università Politecnica delle Marche, 60126 Ancona, Italy

2. Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, 56126 Pisa, Italy

3. Medical Oncology, Fondazione Poliambulanza, 25124 Brescia, Italy

4. Medical Oncology, Azienda Ospedaliero-Universitaria “S. Maria della Misericordia”, 33100 Udine, Italy

5. Medical Oncology, Azienda Ospedaliero-Universitaria di Cagliari, 09042 Monserrato (CA), Cagliari, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The relationship between LDH and GLIM criteria for cancer cachexia: Systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-07

2. Metastatik kolorektal kanserde regorafenib tedavi sonuçlarını etkileyen prognostik faktörler;Adıyaman Üniversitesi Sağlık Bilimleri Dergisi;2023-12-31

3. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study;Biomolecules and Biomedicine;2023-06-08

4. Is neutrophil-to-lymphocyte ratio and C-reactive protein the prognostic role in metastatic colorectal cancer using regorafenib?;Journal of Gastrointestinal Oncology;2023-02

5. Key Prognostic Factors Create a Composite Risk Score to Stratify Patients into High- and Low-Treatment Benefit Groups: A Multicenter, Retrospective Data Analysis of 84 Metastatic Colorectal Cancer Patients Treated with Regorafenib as Part of the CORRECT and CONSIGN Trials;Oncology Research and Treatment;2023